

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	Oncostatin M (OSM); leukemia inhibitory factor receptor- α (LIFR; CD118)	A study in mice suggests increasing OSM signaling through LIFR could help treat osteoporosis. In mice, OSM signaling through LIFR led to greater bone formation than that in controls. The increase occurred without a corresponding increase in osteoclast-mediated bone resorption. Next steps include studying the structures of OSM and LIFR.	Unpatented; unlicensed	Walker, E.C. <i>et al. J. Clin. Invest.</i> ; published online Jan. 4, 2010; doi:10.1172/JCI40568 Contact: Natalie A. Sims, St. Vincent's Institute, Melbourne, Victoria, Australia e-mail: nsims@svi.edu.au
		SciBX 3(3); doi:10.1038/scibx.2010.92 Published online Jan. 21, 2010		